Literature DB >> 9889408

Parasite antigen-specific interleukin-10 and antibody reponses predict accelerated parasite clearance in Plasmodium falciparum malaria.

A J Luty1, B Lell, R Schmidt-Ott, L G Lehman, D Luckner, B Greve, P Matousek, K Herbich, D Schmid, S Ulbert, F Migot-Nabias, B Dubois, P Deloron, P G Kremsner.   

Abstract

Using strict inclusion criteria, we conducted a hospital-based, case-control study in which 100 Gabonese children with severe Plasmodium falciparum malaria were matched for age, gender and provenance with 100 children presenting with mild malaria. Parasite antigen-specific cellular and humoral immunological responses were measured and compared with post-treatment parasite clearance times in each group. Significantly faster parasite clearance times were associated with in vitro production of IL-10 by acute-phase peripheral blood mononuclear cells (PBMC) in response to both liver and asexual stage parasite antigens, but not with proliferative, IFN-gamma, or TNF responses to the same antigens. In addition, in those children with mild malaria, higher levels of acute-phase antibody responses to liver stage antigen-1 (LSA-1) were associated with faster parasite clearance times, and were correlated with the presence of IL-10 responses to the same antigen. No such associations were found for IL-10 or antibody responses to a range of asexual blood stage antigens. Those with severe malaria had significantly lower levels of anti-LSA-1 antibodies compared to their counterparts with mild malaria. In conclusion, the results of this study suggest that parasite antigen-specific IL-10-mediated antibody responses may play a role in the control of asexual stage parasite multiplication in P. falciparum malaria.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9889408

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  15 in total

1.  Proinflammatory and regulatory cytokines and chemokines in infants with uncomplicated and severe Plasmodium falciparum malaria.

Authors:  E Ayimba; J Hegewald; A Y Ségbéna; R G Gantin; C J Lechner; A Agosssou; M Banla; P T Soboslay
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

2.  Fatal Plasmodium falciparum malaria causes specific patterns of splenic architectural disorganization.

Authors:  Britta C Urban; Tran T Hien; Nicholas P Day; Nguyen H Phu; Rachel Roberts; Emsri Pongponratn; Margret Jones; Nguyen T H Mai; Delia Bethell; Gareth D H Turner; David Ferguson; Nicholas J White; David J Roberts
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

3.  Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum.

Authors:  Collette J Hillier; Lisa A Ware; Arnoldo Barbosa; Evelina Angov; Jeffrey A Lyon; D Gray Heppner; David E Lanar
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

4.  Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A.

Authors:  Clara Brando; Lisa A Ware; Helen Freyberger; April Kathcart; Arnoldo Barbosa; Sylvie Cayphas; Marie-Ange Demoitie; Pascal Mettens; D Gray Heppner; David E Lanar
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

5.  Influence of age and HLA type on interferon-gamma (IFN-gamma) responses to a naturally occurring polymorphic epitope of Plasmodium falciparum liver stage antigen-1 (LSA-1).

Authors:  K Bucci; W Kastens; M R Hollingdale; A Shankar; M P Alpers; C L King; J W Kazura
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

6.  Cytokine responses to Plasmodium falciparum liver-stage antigen 1 vary in rainy and dry seasons in highland Kenya.

Authors:  C C John; P O Sumba; J H Ouma; B L Nahlen; C L King; J W Kazura
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

7.  Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.

Authors:  S Pichyangkul; U Kum-Arb; K Yongvanitchit; A Limsalakpetch; M Gettayacamin; D E Lanar; L A Ware; V A Stewart; D G Heppner; P Mettens; J D Cohen; W R Ballou; M M Fukuda
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

8.  Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen 1 and thrombospondin-related adhesive protein immunodominant epitopes in a highland population from Western Kenya.

Authors:  Ann M Moormann; Peter Odada Sumba; Daniel J Tisch; Paula Embury; Charles H King; James W Kazura; Chandy C John
Journal:  Am J Trop Med Hyg       Date:  2009-09       Impact factor: 2.345

Review 9.  Immunity to liver stage malaria: considerations for vaccine design.

Authors:  Andrew W Taylor-Robinson
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

10.  Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.

Authors:  Daniel Dodoo; Frank Atuguba; Samuel Bosomprah; Nana Akosua Ansah; Patrick Ansah; Helena Lamptey; Beverly Egyir; Abraham R Oduro; Ben Gyan; Abraham Hodgson; Kwadwo A Koram
Journal:  Malar J       Date:  2011-05-01       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.